Cargando…

Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial

BACKGROUND Considering the importance of Helicobacter pylori (H. pylori) eradication, this clinical trial was designed to prospectively evaluate the efficacy of levofloxacin-based, sequential therapy in comparison with quadruple therapy for eradicating H. pylori. METHODS Overall 156 patients with dy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajiani, Eskandar, Alavinejad, Pezhman, Avandi, Nahid, Masjedizadeh, Abdol Rahim, Shayesteh, Ali Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488509/
https://www.ncbi.nlm.nih.gov/pubmed/31049172
http://dx.doi.org/10.15171/mejdd.2018.117
_version_ 1783414650873839616
author Hajiani, Eskandar
Alavinejad, Pezhman
Avandi, Nahid
Masjedizadeh, Abdol Rahim
Shayesteh, Ali Akbar
author_facet Hajiani, Eskandar
Alavinejad, Pezhman
Avandi, Nahid
Masjedizadeh, Abdol Rahim
Shayesteh, Ali Akbar
author_sort Hajiani, Eskandar
collection PubMed
description BACKGROUND Considering the importance of Helicobacter pylori (H. pylori) eradication, this clinical trial was designed to prospectively evaluate the efficacy of levofloxacin-based, sequential therapy in comparison with quadruple therapy for eradicating H. pylori. METHODS Overall 156 patients with dyspepsia and H. pylori infection were included in this study and were randomly allocated to either 10-day sequential therapy group (group A) to receive pantoprazole (40 mg twice daily), amoxicillin (1 gr twice daily), levofloxacin (500 mg twice daily), and tinidazole (500 mg twice daily) (PALT) or 14-day quadruple therapy group (group B) to receive pantoprazole, clarithromycin, bismuth subcitrate, and amoxicillin (PABC). At the end of the study the eradication rate in each group was assessed by urea breath test (UBT). RESULTS Age range of the participants was 18-65 years (average 36.9 years) and 50% of them (78 patients) were men. 78 patients were allocated to group A and 78 patients to groupe B. After antibiotic therapy, all the patients received acid suppression therapy with Proton Pump Inhibitor (PPI) for 4 weeks and then the eradication rate was confirmed by UBT (Heli FAN plus 13C, Germany). Before performing UBT, all the participants were requested to halt consumption of PPI for at least 1 week. During the treatment there was not any major complication but in group A (sequential therapy), two patients complained of minor complications including musculoskeletal pain. None of the patients in group B had any complaint or side effect. The rate of H. pylori eradication in group A was 78.2% (61 patients) while this rate in group B was 83.3% (65 patients) with no significant difference between the two groups (p = 0.42). In subgroup analysis, the rate of eradication among men in group A and B were 76.9% and 89.7%, respectively (p = 0.22) while the eradication rate among women were 79.4% and 76.9%, respectively (p = 1.00). CONCLUSION It seems that levofloxacin base sequential therapy does not have any advantage in comparison with quadruple regimen and until finding any more effective short course therapy for H. Pylori eradication; we encourage quadruple regimen to be used as the first line therapy.
format Online
Article
Text
id pubmed-6488509
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Iranian Association of Gastroerterology and Hepatology
record_format MEDLINE/PubMed
spelling pubmed-64885092019-05-02 Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial Hajiani, Eskandar Alavinejad, Pezhman Avandi, Nahid Masjedizadeh, Abdol Rahim Shayesteh, Ali Akbar Middle East J Dig Dis Original Article BACKGROUND Considering the importance of Helicobacter pylori (H. pylori) eradication, this clinical trial was designed to prospectively evaluate the efficacy of levofloxacin-based, sequential therapy in comparison with quadruple therapy for eradicating H. pylori. METHODS Overall 156 patients with dyspepsia and H. pylori infection were included in this study and were randomly allocated to either 10-day sequential therapy group (group A) to receive pantoprazole (40 mg twice daily), amoxicillin (1 gr twice daily), levofloxacin (500 mg twice daily), and tinidazole (500 mg twice daily) (PALT) or 14-day quadruple therapy group (group B) to receive pantoprazole, clarithromycin, bismuth subcitrate, and amoxicillin (PABC). At the end of the study the eradication rate in each group was assessed by urea breath test (UBT). RESULTS Age range of the participants was 18-65 years (average 36.9 years) and 50% of them (78 patients) were men. 78 patients were allocated to group A and 78 patients to groupe B. After antibiotic therapy, all the patients received acid suppression therapy with Proton Pump Inhibitor (PPI) for 4 weeks and then the eradication rate was confirmed by UBT (Heli FAN plus 13C, Germany). Before performing UBT, all the participants were requested to halt consumption of PPI for at least 1 week. During the treatment there was not any major complication but in group A (sequential therapy), two patients complained of minor complications including musculoskeletal pain. None of the patients in group B had any complaint or side effect. The rate of H. pylori eradication in group A was 78.2% (61 patients) while this rate in group B was 83.3% (65 patients) with no significant difference between the two groups (p = 0.42). In subgroup analysis, the rate of eradication among men in group A and B were 76.9% and 89.7%, respectively (p = 0.22) while the eradication rate among women were 79.4% and 76.9%, respectively (p = 1.00). CONCLUSION It seems that levofloxacin base sequential therapy does not have any advantage in comparison with quadruple regimen and until finding any more effective short course therapy for H. Pylori eradication; we encourage quadruple regimen to be used as the first line therapy. Iranian Association of Gastroerterology and Hepatology 2018-10 2018-09-06 /pmc/articles/PMC6488509/ /pubmed/31049172 http://dx.doi.org/10.15171/mejdd.2018.117 Text en © 2018 The Author(s) This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Hajiani, Eskandar
Alavinejad, Pezhman
Avandi, Nahid
Masjedizadeh, Abdol Rahim
Shayesteh, Ali Akbar
Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title_full Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title_fullStr Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title_full_unstemmed Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title_short Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial
title_sort comparison of levofloxacin-based, 10-day sequential therapy with 14-day quadruple therapy for helicobacter pylori eradication: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488509/
https://www.ncbi.nlm.nih.gov/pubmed/31049172
http://dx.doi.org/10.15171/mejdd.2018.117
work_keys_str_mv AT hajianieskandar comparisonoflevofloxacinbased10daysequentialtherapywith14dayquadrupletherapyforhelicobacterpylorieradicationarandomizedclinicaltrial
AT alavinejadpezhman comparisonoflevofloxacinbased10daysequentialtherapywith14dayquadrupletherapyforhelicobacterpylorieradicationarandomizedclinicaltrial
AT avandinahid comparisonoflevofloxacinbased10daysequentialtherapywith14dayquadrupletherapyforhelicobacterpylorieradicationarandomizedclinicaltrial
AT masjedizadehabdolrahim comparisonoflevofloxacinbased10daysequentialtherapywith14dayquadrupletherapyforhelicobacterpylorieradicationarandomizedclinicaltrial
AT shayestehaliakbar comparisonoflevofloxacinbased10daysequentialtherapywith14dayquadrupletherapyforhelicobacterpylorieradicationarandomizedclinicaltrial